Castle Biosciences (CSTL) Q2 2026 Earnings Call Transcript
Castle Biosciences (CSTL) reported Q2 2026 total revenue of $103.5 million, up 20.1% from $86.2 million a year earlier, driven by TissueCypher volume and ASP gains. Management raised 2026 revenue guidance to $365 million to $375 million. Adjusted gross margin was 76.3% and adjusted EBITDA $12.4 million. Cash was $266.8 million at June 30, 2026.
How this was made
The 30-second read
Why it matters
Traders can update 2026 revenue expectations based on the raised guidance and track adoption indicators (TissueCypher volume growth, AdvanceAD-Tx orders) while monitoring margin and reimbursement-related uncertainties (DecisionDx-SCC coverage).
Market read
The most tradable elements are the raised 2026 revenue outlook and the quantified adoption metrics, which can drive near-term sentiment and forward estimates.
What to watch
DecisionDx-SCC volume declined after Medicare coverage change, and the proposed AdvanceAD-Tx Medicare crosswalk rate may not translate into near-term cash flow timing; also, lab investment intensity could pressure margins further.
Background
The article summarizes Castle Biosciences’ Q2 2026 earnings call, including revenue, margins, expenses, and full-year guidance, plus reimbursement and pipeline updates.
Ticker impact
Castle Biosciences raised 2026 revenue guidance to $365M-$375M and reported Q2 revenue of $103.5M, up 20.1% YoY.
Likely positive bias for the stock into the next few sessions as traders price in higher 2026 revenue, tempered by gross margin and operating expense pressure.
The article provides multiple fresh, decision-relevant datapoints: raised full-year revenue range, Q2 revenue and volume metrics, and updated margin/expense figures. However, it is a transcript summary without explicit consensus comparisons, limiting precision on magnitude of repricing.
Market effects
Signals continued adoption momentum in molecular diagnostics (dermatology and gastroenterology) but highlights reimbursement and margin sensitivity.
Primarily US healthcare diagnostics sentiment; no explicit regional spillover beyond Medicare reimbursement dynamics.
Limited direct global relevance; reimbursement and FDA pathway items are US-centric.
Counterpoint
Margin fell year over year (adjusted gross margin 76.3% vs 79.5%) and operating expenses rose sharply, so the guidance raise could be partially offset by profitability dilution if adoption costs persist.
Key entities
- companyCastle Biosciences
Reported Q2 2026 results and raised 2026 revenue guidance; discussed test volumes, margins, expenses, and reimbursement/pipeline progress.
- productDecisionDx-SCC
Squamous cell carcinoma gene expression test; volume declined after Medicare coverage change and management discussed potential return of coverage.
- productTissueCypher
Spatialomics test for Barrett’s progression risk; volume grew 63.4% YoY and management guided 50% to 52% full-year growth.
- productAdvanceAD-Tx
Atopic dermatitis gene expression profile test; management reported 1,000+ orders delivered and discussed Medicare crosswalk rate proposal.
- partnerSciBase
Collaborator on the DETECT-AD study referenced in the call.
